The DOI matches its Crossref record; 73 of the 76 references it cites were found in a registry or an index.
CNS Drug Delivery Systems: Novel Approaches
Abstract
The brain is a delicate organ, and nature has very efficiently protected it. The brain is shielded against potentially toxic substances by the presence of two barrier systems: the blood brain barrier (BBB) and the blood cerebrospinal fluid barrier (BCSFB). Unfortunately, the same mechanisms that protect it against intrusive chemicals can also frustrate therapeutic interventions. Despite aggressive research, patients suffering from fatal and/or debilitating central nervous system (CNS) diseases, such as brain tumours, HIV encephalopathy, epilepsy, cerebrovascular diseases and neurodegenerative disorders, far outnumber those dying of all types of systemic cancers or heart diseases. The abysmally low number of potential therapeutics reaching commercial success is primarily due to the complexity of the CNS drug development. The clinical failure of many probable candidates is often, ascribable to poor delivery methods which do not pervade the unyielding BBB. It restricts the passive diffusion of many drugs into the brain and constitutes a significant obstacle in the pharmacological treatment of central nervous system (CNS) disorders. General methods that can enhance drug delivery to the brain are, therefore, of great pharmaceutical interest. Various strategies like non-invasive methods, including drug manipulation encompassing transformation into lipophilic analogues, prodrugs, chemical drug delivery, carrier-mediated drug delivery, receptor/vector mediated drug delivery and intranasal drug delivery, which exploits the olfactory and trigeminal neuronal pathways to deliver drugs to the brain, are widely used. On the other hand the invasive methods which primarily rely on disruption of the BBB integrity by osmotic or biochemical means, or direct intracranial drug delivery by intracerebroventricular, intracerebral or intrathecal administration after creating reversible openings in the head, are recognised. Extensive review pertaining specifically, to the patents relating to drug delivery across the CNS is currently available. However, many patents e.g. US63722506, US2002183683 etc., have been mentioned in a few articles. It is the objective of this article to expansively review drug delivery systems for CNS by discussing the recent patents available.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One of the most common challenge is the difficulty in delivering agents such as drugs, nucleic acids, proteins, imaging agents and other macromolecules to the CNS across the peripheral barriers, namely blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB), particularly the BBB (Pathan et al., 2009; Wong et al., 2012).”
From Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs (2020) · cites this paper as Pathan et al., 2009
Citations
Cites
Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,836
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,158
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE
Endicott, J. A., & Ling, V. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.001033 · Cited by 2,071
Cordon‐Cardo, C., O’Brien, J. P., Casals, D., Rittmann-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Nano-engineering block copolymer aggregates for drug delivery
Allen, C., Maysinger, D., & Eisenberg, A. (1999) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00058-2 · Cited by 1,358
Polymeric micelles—A new generation of colloidal drug carriers
Jones, M.-C., & Leroux, J.-C. (1999) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(99)00039-9 · Cited by 1,256
Amphiphilic block copolymers for drug delivery
Adams, M. L., Lavasanifar, A., & Kwon, G. S. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10397 · Cited by 1,078
Nanoparticulate systems for brain delivery of drugs
Kreuter, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.015 · Cited by 965
Levin, V. A. (1980) · Journal of Medicinal Chemistry · doi:10.1021/jm00180a022 · Cited by 817
Cited by
Sorted by citations
Modern methods for delivery of drugs across the blood–brain barrier
Chen, Y., & Liu, L. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.010 · Cited by 1,038
Characterization of a microfluidic in vitro model of the blood-brain barrier (μBBB)
Booth, R., & Kim, H. (2012) · Lab on a Chip · doi:10.1039/c2lc40094d · Cited by 746
Pardeshi, C. V., & Belgamwar, V. S. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.790887 · Cited by 482
Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease
Fonseca‐Santos, B., Chorilli, M., & Gremião, M. P. D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87148 · Cited by 320
Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305
“…difficulty in delivering agents such as drugs, nucleic acids, proteins, imaging agents and other macromolecules to the CNS across the peripheral barriers, namely blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB), particularly the BBB (Pathan et al., 2009; Wong et al., 2012).”
Background
Metadata
- Authors
- Pathan, S., Iqbal, Z., Zaidi, S., Talegaonkar, S., Vohra, D., Jain, G., Azeem, A., Jain, N., Lalani, J., Khar, R., & Ahmad, F.
- Affiliations
- Jamia Hamdard (IN)
- Corresponding author
- Ahmad, Farhan
- Venue
- Recent Patents on Drug Delivery & Formulation
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-01-01
- Volume
- 3
- Issue
- 1
- Pages
- 71-89
- ISSN
- 1872-2113 (ISSN-L)
- OpenAlex
- W2163840515
- Cited by
- 193
- References
- 76
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 14 · 2023: 12 · 2022: 17 · 2021: 12 · 2020: 9 · 2019: 14 · 2018: 12 · 2017: 10 · 2016: 16 · 2015: 16 · 2014: 11 · 2013: 16 · 2012: 9
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Recent Patents on Drug Delivery & Formulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- brain drug delivery, blood-brain barrier, blood-CSF barrier, brain tumors, neurodegenerative diseases, epilepsy, HIV encephalopathy, cerebrovascular disease, prodrugs, intranasal drug delivery, olfactory pathway, receptor-mediated drug delivery, blood-brain barrier disruption, intrathecal drug delivery, intracerebroventricular administration, patents
- MeSH terms
- Biological Transport, Blood-Brain Barrier, Brain, Central Nervous System Diseases, Pharmaceutical Preparations, Humans, Patents as Topic, Technology, Pharmaceutical, United States, Drug Design, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
